GENFIT’s Drug Nears EU Market Approval
Company Announcements

GENFIT’s Drug Nears EU Market Approval

Genfit SA (GNFT) has released an update.

GENFIT, a biopharmaceutical company, announced the European Medicines Agency’s positive opinion on Ipsen’s Iqirvo® (elafibranor) for treating Primary Biliary Cholangitis, bringing it closer to EU market authorization. Elafibranor, developed by GENFIT, has been marketed in the US since June 2024 and awaits a final decision in the EU for the second half of 2024. The company continues to focus on advancing treatments for rare liver diseases and has a diverse R&D portfolio.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenfit’s Revenue Surge Driven by Key Milestone
TipRanks Auto-Generated NewsdeskGenfit’s Iqirvo Wins EU Approval for Liver Condition
TipRanks Auto-Generated NewsdeskGENFIT SA Showcases Robust 2024 Financial Health
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App